Virology News
66.6K views | +0 today
Follow
 
Scooped by Ed Rybicki
onto Virology News
Scoop.it!

Production of protective bluetongue virus-like particle vaccine in plants

Production of protective bluetongue virus-like particle vaccine in plants | Virology News | Scoop.it

Plant expression systems based on nonreplicating virus-based vectors can be used for the simultaneous expression of multiple genes within the same cell. They therefore have great potential for the production of heteromultimeric protein complexes. This work describes the efficient plant-based production and assembly of Bluetongue virus-like particles (VLPs), requiring the simultaneous expression of four distinct proteins in varying amounts. Such particles have the potential to serve as a safe and effective vaccine against Bluetongue virus (BTV), which causes high mortality rates in ruminants and thus has a severe effect on the livestock trade. Here, VLPs produced and assembled in Nicotiana benthamiana using the cowpea mosaic virus-based HyperTrans (CPMV-HT) and associated pEAQ plant transient expression vector system were shown to elicit a strong antibody response in sheep. Furthermore, they provided protective immunity against a challenge with a South African BTV-8 field isolate.

 

The results show that transient expression can be used to produce immunologically relevant complex heteromultimeric structures in plants in a matter of days. The results have implications beyond the realm of veterinary vaccines and could be applied to the production of VLPs for human use or the coexpression of multiple enzymes for the manipulation of metabolic pathways.

 Generic reovirus-like particle by Russell Kightley Media
Ed Rybicki's insight:

While this has not been subject to the same hype as the FMDV VLPs featured here and all over the media recently, it is at least as big a deal - and yes, we are involved, and yes, we are highly stoked with what we did.

 

Because this is a four-protein virus-like particle, expressed via transient expression in N benthamiana, and assembled in yields high enough to allow purification of particles that were protective in a live virus challenge experiment in sheep.

 

Yes, protective in actual sheep, and competitive with the standard attentuated live virus vaccine - which is a seriously big deal!

 

Plus the electron micrographs of the particles are SO cool.  Congratulations, Eva and team, you have done really, really well.

Frank Sainsbury's comment, May 17, 2013 3:45 AM
Hear, hear!!
Virology News
Topical news snippets about viruses that affect people.  And other things. Like Led Zeppelin. And zombies B-)
Curated by Ed Rybicki
Your new post is loading...
Your new post is loading...
Scooped by Ed Rybicki
Scoop.it!

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine this month | Virology News | Scoop.it
Bharat Biotech completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Study identifies broad-spectrum antibody that neutralizes SARS-CoV-2 variants of concern

Study identifies broad-spectrum antibody that neutralizes SARS-CoV-2 variants of concern | Virology News | Scoop.it
Scientists have described the identification and therapeutic evaluation of an antibody that broadly neutralizes major variants of SARS-CoV-2, including the alpha, beta, delta, and omicron variants.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

U.S. Trailer for Kirill Serebrennikov's Petrov's Flu Takes Hallucinatory Trip Through Post-Soviet Russia

U.S. Trailer for Kirill Serebrennikov's Petrov's Flu Takes Hallucinatory Trip Through Post-Soviet Russia | Virology News | Scoop.it
Russian director Kirill Serebrennikov has been invited to back-to-back Cannes for his latest work, premiering Petrov's Flu last year and Tchaikovsky's Wife this...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Moderna takes mRNA influenza candidate into Phase 3 trial

Moderna takes mRNA influenza candidate into Phase 3 trial | Virology News | Scoop.it
Moderna has dosed the first participants in a Phase 3 study of the company’s seasonal influenza vaccine candidate, mRNA-1010....
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

How Long Can the Coronavirus Keep Reinfecting Us?

How Long Can the Coronavirus Keep Reinfecting Us? | Virology News | Scoop.it
No one knows exactly what this will look like—only that it’s guaranteed to keep happening.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Virologist: Monkeypox genome doesn't explain outbreak

Virologist: Monkeypox genome doesn't explain outbreak | Virology News | Scoop.it
"There are no new, large mutations that could account for the change in [monkeypox] transmission," says virologist Heather Koehler.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Hippo pathway stops moles turning into deadly melanomas

Hippo pathway stops moles turning into deadly melanomas | Virology News | Scoop.it
A study that clarifies how some harmless moles grow into deadly melanomas could lead to new drug targets for the successful treatment of cancer.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Quick loss of smell predicts dementia brain changes

Quick loss of smell predicts dementia brain changes | Virology News | Scoop.it
A rapid decline in sense of smell during a period of normal cognition predicted multiple features of Alzheimer's disease, report researchers.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Thousands of dead migrant seabirds wash up on Canada shore, avian flu suspected

Thousands of dead migrant seabirds wash up on Canada shore, avian flu suspected | Virology News | Scoop.it
The Canadian Food Inspection Agency has confirmed 13 positive cases of highly pathogenic avian influenza in Newfoundland since May...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

What you should know about monkeypox

What you should know about monkeypox | Virology News | Scoop.it
Amid a steady rise in monkeypox cases worldwide, an expert explains how the virus is transmitted, who is at risk, and how vaccines can control the spread.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

COVID vax patch beats needles for fighting variants

COVID vax patch beats needles for fighting variants | Virology News | Scoop.it
A new patch "has the potential to offer a new—and more effective—weapon in our arsenal, at a time where new variants are mutating at a rapid rate."...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Genetic diversity in the capsid protein of Porcine circovirus type 3 in Vietnam from 2018 to 2019 

Porcine circovirus type 3 (PCV3) was first detected in 2016 and has been recorded in many pig-producing countries around the world. PCV3 was quickly reported in Vietnamese pig farms. PCV3 was found in complex cases with multiple clinical syndromes in swine.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Global Monkeypox Vaccine Race Sparks Fears That Poorer Nations Will Lose Out

A scramble for monkeypox vaccines is under way, with 35 countries vying for access to the 16.4m doses that exist so far, according to the World Health...
Ed Rybicki's insight:
FEARS?? They're losing out already!!
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

A universal influenza mRNA vaccine candidate boosts T-cell responses and reduces zoonotic influenza virus disease in ferrets | bioRxiv

A universal influenza mRNA vaccine candidate boosts T-cell responses and reduces zoonotic influenza virus disease in ferrets | bioRxiv | Virology News | Scoop.it
bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Effectiveness of influenza vaccines in adults with chronic liver disease: A systematic review and meta-analysis

Effectiveness of influenza vaccines in adults with chronic liver disease: A systematic review and meta-analysis | Virology News | Scoop.it
OBJECTIVES: Patients with liver disease frequently require hospitalisation with infection often the trigger. Influenza vaccination is an effective infection prevention strategy in healthy and elderly but is often perceived less beneficial in patients with liver disease. We investigated whether influenza vaccination triggered serological response and prevented hospitalisation and death in liver disease.DESIGN: Systematic review and meta-analysis.DATA SOURCES: MEDLINE, EMBASE, PubMed and CENTRAL up to January 2019.ELIGIBILITY CRITERIA: Randomised or observational studies of the effects of influenza vaccine in adults with liver disease.DATA EXTRACTION AND SYNTHESIS: Two reviewers screened studies, extracted data and assessed risk of bias and quality of evidence. Primary outcomes were all-cause hospitalisation and mortality. Secondary outcomes were cause-specific hospitalisation and mortality, and serological vaccine response. Random-effects meta-analysis was used to estimate pooled effects of vaccination.RESULTS: We found 10 041 unique records, 286 were eligible for full-text review and 12 were included. Most patients had viral liver disease. All studies were of very low quality. Liver patients both with and without cirrhosis mounted an antibody response to influenza vaccination, and vaccination was associated with a reduction in risk of hospital admission from 205/1000 to 149/1000 (risk difference -0.06, 95% CI -0.07 to 0.04) in patients with viral liver disease. Vaccinated patients were 27% less likely to be admitted to hospital compared with unvaccinated patients (risk ratio 0.73, 95% CI 0.66 to 0.80). No effect against all-cause or cause-specific mortality or cause-specific hospitalisation was found.CONCLUSIONS: The low quantity and quality of the evidence means that the protective vaccine effect may be uncertain. Considering the high risk of serious health outcomes from influenza infection in patients with liver disease and the safety and low cost of vaccination, overall, the potential benefits of seasonal vaccination both to patients and the healthcare systems are likely to outweigh the costs and risks associated with vaccination.PROSPERO REGISTRATION NUMBER: CRD42017067277.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Spontaneous hydrogen peroxide may explain flu seasonality

Spontaneous hydrogen peroxide may explain flu seasonality | Virology News | Scoop.it
Further investigation into the spontaneous formation of hydrogen peroxide from water may explain why flu cases peak in winter.
Ed Rybicki's insight:
Interesting: makes some assumptions that are not as general as they think (LMICs will not tend to heat houses like the US does), but thinking of humid air interacting with surfaces as producing natural disinfectants is quite intriguing?
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Reinfection will be part of the pandemic for months to come. Each repeat illness raises the risk of long COVID

Reinfection will be part of the pandemic for months to come. Each repeat illness raises the risk of long COVID | Virology News | Scoop.it
SARS-CoV-2 is not the first virus to cause unexplained chronic illness, but the sheer size of this pandemic means more people will develop long COVID.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Enhanced viral infectivity and reduced interferon production are associated with high pathogenicity for influenza viruses

bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Lung proteins can aid or hamper SARS-CoV-2 infections

Lung proteins can aid or hamper SARS-CoV-2 infections | Virology News | Scoop.it
New research is "a step forward in understanding viral infection pathways and paves the way for research toward better treatments in the future."...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Universal Influenza B Vaccine Induces Broad, Sustained Protection

Universal Influenza B Vaccine Induces Broad, Sustained Protection | Virology News | Scoop.it
A new universal flu vaccine protects against influenza B viruses, offering broad defense against different strains and improved immune protection, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Can bats help prevent the next pandemic?

Can bats help prevent the next pandemic? | Virology News | Scoop.it
Bats can teach us a lot about how to manage, and maybe even prevent, future pandemics, researchers say.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Nanobody busts into brain cells to unclump proteins

Nanobody busts into brain cells to unclump proteins | Virology News | Scoop.it
Researchers have developed a nanobody that can get through the tough exterior of mouse brain cells and untangle misshapen proteins.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis

In this systematic review and network meta-analysis, all 4 antiviral agents assessed were associated with shortening TTAS; zanamivir was associated with the shortest TTAS, and baloxavir was associated with reduced rate of influenza-related complications.
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults

Healthy subjects <45 years old (young adults) or >65 (elderly adults) were randomized in double-blind fashion to receive intramuscularly subv...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Microparticles could form self-boosting vaccines

Microparticles could form self-boosting vaccines | Virology News | Scoop.it
New research suggests microparticles able to release their payloads at different times could form the basis of self-boosting vaccine courses.
No comment yet.